StreetAlpha.app
Home › Stocks › ROIV

Roivant Sciences Ltd. (ROIV)

Healthcare
$38.71
▲ +0.26%
LAST CLOSE · NOV 17

Roivant is a biopharmaceutical company in London developing medicines for immune, inflammatory and lung diseases. It last closed at $38.71 on Nov 17, up 0.26% on the day. ROIV reports earnings on Fri, Feb 5, 2027. The average 12-month price target from 6 analysts is $51.67 (+33.5% from the last close), with a high of $56.00 and a low of $48.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in ROIV, 100% of them bullish and 0% bearish. In the past 30 days there were 5 dark pool prints totaling $11.4M, the largest $7.2M.

AI Auto Pilots
Is ROIV in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$41.1M
+102.1% vs a year ago
Net income
−$344.4M
−838.2% margin
EPS (diluted)
−$0.58
Free cash flow
−$39.4M
−96.0% margin
Valuation
Market cap
$28.0B
724.6M shares
P/E
–
No P/E while losing money
Price to sales
682.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.6B
At Sep 30
Shareholder equity
$4.0B
Shares outstanding
724.6M
At Nov 3
Fiscal year endsMarch
ExchangeNasdaq
Financials history
FY2022: $55.3M$55.3MFY2022FY2023: $31.5M$31.5MFY2023FY2024: $32.7M$32.7MFY2024FY2025: $29.1M$29.1MFY2025FY2026: $8.3M$8.3MFY2026

From ROIV's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Feb 5
2027 · Time not announced
Consensus EPS forecast
-$0.36
$50.6M revenue est.
Year-ago EPS
-$0.24
Same quarter last year
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
6 Buy0 Hold0 Sell
Each firm's latest rating on ROIV in the past 90 days
Average 12-month target
$51.67
▲ 33.5% upside

Based on 6 analysts who set a price target on ROIV in the past 90 days. The average target is $51.67, with a high of $56.00 and a low of $48.00, compared with the last close of $38.71.

Low $48.00Avg $51.67High $56.00
Blue marker: last close $38.71
Highest target$56.00
Average target$51.67
Lowest target$48.00
Latest rating changes
GuggenheimTarget raised
Nov 16Buy$46 → $48
HC Wainwright & Co.Target raised
Nov 10Buy$47 → $48
CitigroupTarget raised
Oct 28Buy$46 → $56
StifelInitiated
Sep 17Buy$51
TD CowenTarget raised
Sep 9Buy$41 → $55
DateFirmActionRatingPrice target
Nov 16GuggenheimTarget raisedBuy$46 → $48
Nov 10HC Wainwright & Co.Target raisedBuy$47 → $48
Oct 28CitigroupTarget raisedBuy$46 → $56
Sep 17StifelInitiatedBuy$51
Sep 9TD CowenTarget raisedBuy$41 → $55
Loading…

Technical Analysis

ROIV · as of the Nov 17 close · updated after every close
Uptrend

The stock is 2% above its 20 day and 4% above its 50 day average. It is 16% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 54). The nearest support is the Pivot at $38.28, and the nearest resistance the Pivot R1 at $39.17.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNormal
VolatilityHigh, 3.9%/day
Key levels
$42.5052 week high+9.8%
$42.24Swing high (Nov 11)+9.1%
$39.17Pivot R1+1.2%
$38.71Last close
$38.28Pivot−1.1%
$38.0520 day average−1.7%
$37.82Pivot S1−2.3%
$37.3250 day average−3.6%
$36.37100 day average−6.0%
$35.71Swing low (Aug 24)−7.7%
$32.48200 day average−16.1%
$19.9652 week low−48.4%
Indicators
RSI (14)53.54Middle of its rangeNeutral
MACD0.94Above its signal lineBullish
Stochastic50.8Middle of its rangeNeutral
ADX (14)18.8No clear trend
Williams %R-52.8Oversold below −80, overbought above −20Neutral
CCI (20)10.8Oversold below −100, overbought above 100Neutral
Rate of change+7.4%Change over 10 sessionsBullish
ATR (14)$1.53Typical daily range, 3.9% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ROIV

What happened before

See how ROIV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ROIV usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ROIV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
2
100%
Bearish
0
0%
Date span
Oct 6 – Oct 6
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
5
Notional
$11.4M
Largest print
$7.2M
Loading…

ROIV Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲330 buying vs 209 selling
  • ▲Held by funds +1.8 pts
  • ▲Funds holding +19
  • ▼Superinvestors: 2 added, 3 cut
  • ▲Put/call 0.03 to 0.00
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding522503+3.8%
In funds' top 102115+40.0%
Held by funds79.9%78.2%+1.8 pts
New / increased99 / 23197 / 204+9.6%
Reduced / sold out133 / 76140 / 40+16.1%
Put/call ratio0.000.03−92.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ROIV institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ROIV is in one of them and how their past ROIV trades turned out.

ROIV in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ROIV in an article yet. Here's the latest on the wider market.

ROIV Congress Trades

All congress trades →
Trades, 12 months
3
Buys
1
33%
Sells
2
67%
People
1
Last filed Nov 21
Who traded ROIV · since 2025
Latest 4 filings
$1K – $15KTraded Oct 31, 2025Filed Nov 21, 2025
$1K – $15KTraded Oct 30, 2025Filed Nov 21, 2025
$1K – $15KTraded Oct 30, 2025Filed Nov 21, 2025
$1K – $15KTraded Jun 17, 2025Filed Aug 13, 2025
PersonTypeAmountTradedFiledDelay
Lisa McClainR · MISell$1K – $15KOct 31, 2025Nov 21, 202521 d
Lisa McClainR · MIBuy$1K – $15KOct 30, 2025Nov 21, 202522 d
Lisa McClainR · MISell$1K – $15KOct 30, 2025Nov 21, 202522 d
Lisa McClainR · MIBuy$1K – $15KJun 17, 2025Aug 13, 202557 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Roivant Sciences

Roivant is a biopharmaceutical company based in London. It develops medicines for patients with immune and inflammatory conditions, including dermatomyositis, non-infectious uveitis and rheumatoid arthritis, as well as pulmonary hypertension linked to interstitial lung disease. Its product candidates are investigational and still require health authority approval. The company also helps build early-stage drug discovery and health technology companies.

Headquarters
London